Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023

Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN, May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:

Related Keywords

United States ,Ireland ,Texas ,China ,Dublin ,American ,Gewinn Nur ,Rob Iannone ,Zymework Azymetric ,Kristin Bhavnani ,Andrean Flynn ,Commission File No ,Department Of Gastrointestinal Medical Oncology ,American Society Of Clinical Oncology ,European Medicines Agency ,Prnewswire Jazz Pharmaceuticals ,Drug Administration ,Jazz Pharmaceuticals ,Exchange Commission ,Department Of Investigational Cancer Therapeutics ,Nasdaq ,University Of Texas Md Anderson Cancer Center ,Beigene Ltd ,Head Of Global Corporate Communications ,Clinical Oncology ,Annual Meeting ,Gastrointestinal Medical Oncology ,Investigational Cancer Therapeutics ,Cancer Center ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Drug Evaluation ,Jazz Pharmaceutical ,Commission File ,Jazz Pharmaceutical Annual Report ,Quarterly Report ,Global Corporate ,Jazz ,Pharmaceuticals ,Most ,Zanidatamab ,Investor ,Ebcast ,Pune ,023 ,